Newsroom

CSRxP Applauds PhRMA’s Newfound Commitment to R&D

“If PhRMA’s members are serious about their commitment to affordability, we invite them to join us in supporting common-sense, bipartisan reforms like the CREATES and FAST Generics Acts that address equally-egregious, though less-publicized, anticompetitive abuses as the ones that prompted this change in policy.”

Read more

CSRxP Statement on President Trump’s Meeting With Big Pharma Executives

“Transparency is one of the keys to market-based reforms that will lead to lower prices and ensure that taxpayers receive a real return on their investment.”

Read more

CSRxP Launches National Campaign to Hold Big Pharma Accountable

CSRxP has launched a national campaign as part of a multi-million-dollar effort to hold Big Pharma accountable for their out-of-control prescription drug prices. Because Big Pharma blocks competition to maintain monopolies on medicines, they can set any price they want.

Read more

CSRxP Applauds Introduction of the CREATES Act

“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety.”

Read more